Literature DB >> 33208393

Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways.

Trang H Pham1, Thijs J Hagenbeek1, Ho-June Lee1, Matthew T Chang2, Anwesha Dey3, Jason Li4, Christopher M Rose5, Eva Lin1, Mamie Yu1, Scott E Martin1, Robert Piskol4, Jennifer A Lacap6, Deepak Sampath6, Victoria C Pham5, Zora Modrusan7, Jennie R Lill5, Christiaan Klijn4, Shiva Malek1.   

Abstract

Hippo pathway dysregulation occurs in multiple cancers through genetic and nongenetic alterations, resulting in translocation of YAP to the nucleus and activation of the TEAD family of transcription factors. Unlike other oncogenic pathways such as RAS, defining tumors that are Hippo pathway-dependent is far more complex due to the lack of hotspot genetic alterations. Here, we developed a machine-learning framework to identify a robust, cancer type-agnostic gene expression signature to quantitate Hippo pathway activity and cross-talk as well as predict YAP/TEAD dependency across cancers. Further, through chemical genetic interaction screens and multiomics analyses, we discover a direct interaction between MAPK signaling and TEAD stability such that knockdown of YAP combined with MEK inhibition results in robust inhibition of tumor cell growth in Hippo dysregulated tumors. This multifaceted approach underscores how computational models combined with experimental studies can inform precision medicine approaches including predictive diagnostics and combination strategies. SIGNIFICANCE: An integrated chemicogenomics strategy was developed to identify a lineage-independent signature for the Hippo pathway in cancers. Evaluating transcriptional profiles using a machine-learning method led to identification of a relationship between YAP/TAZ dependency and MAPK pathway activity. The results help to nominate potential combination therapies with Hippo pathway inhibition.This article is highlighted in the In This Issue feature, p. 521. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2020        PMID: 33208393     DOI: 10.1158/2159-8290.CD-20-0706

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  11 in total

1.  A 3-Gene Random Forest Model to Diagnose Non-obstructive Azoospermia Based on Transcription Factor-Related Henes.

Authors:  Ranran Zhou; Jingjing Liang; Qi Chen; Hu Tian; Cheng Yang; Cundong Liu
Journal:  Reprod Sci       Date:  2022-06-17       Impact factor: 3.060

2.  Hippo pathway regulation by phosphatidylinositol transfer protein and phosphoinositides.

Authors:  Fu-Long Li; Vivian Fu; Guangbo Liu; Tracy Tang; Andrei W Konradi; Xiao Peng; Esther Kemper; Benjamin F Cravatt; J Matthew Franklin; Zhengming Wu; Joshua Mayfield; Jack E Dixon; William H Gerwick; Kun-Liang Guan
Journal:  Nat Chem Biol       Date:  2022-07-04       Impact factor: 16.174

3.  Combined Inhibition of FOSL-1 and YAP Using siRNA-Lipoplexes Reduces the Growth of Pancreatic Tumor.

Authors:  Lara Diego-González; Andrea Fernández-Carrera; Ana Igea; Amparo Martínez-Pérez; M Elisabete C D Real Oliveira; Andreia C Gomes; Carmen Guerra; Mariano Barbacid; África González-Fernández; Rosana Simón-Vázquez
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

4.  SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas.

Authors:  Eliot Y Zhu; Jesse D Riordan; Marion Vanneste; Michael D Henry; Christopher S Stipp; Adam J Dupuy
Journal:  NPJ Precis Oncol       Date:  2022-10-21

5.  Machine learning approach informs biology of cancer drug response.

Authors:  Eliot Y Zhu; Adam J Dupuy
Journal:  BMC Bioinformatics       Date:  2022-05-17       Impact factor: 3.307

Review 6.  Current Research Progress of the Role of LncRNA LEF1-AS1 in a Variety of Tumors.

Authors:  Qingyuan Zheng; Xiao Yu; Menggang Zhang; Shuijun Zhang; Wenzhi Guo; Yuting He
Journal:  Front Cell Dev Biol       Date:  2021-12-20

7.  Curcumenol mitigates chondrocyte inflammation by inhibiting the NF‑κB and MAPK pathways, and ameliorates DMM‑induced OA in mice.

Authors:  Xiao Yang; Yifan Zhou; Zhiqian Chen; Chen Chen; Chen Han; Xunlin Li; Haijun Tian; Xiaofei Cheng; Kai Zhang; Tangjun Zhou; Jie Zhao
Journal:  Int J Mol Med       Date:  2021-08-26       Impact factor: 4.101

Review 8.  Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine.

Authors:  Evan R Barry; Vladimir Simov; Iris Valtingojer; Olivier Venier
Journal:  Cells       Date:  2021-10-11       Impact factor: 6.600

9.  Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer.

Authors:  Anna Gogleva; Dimitris Polychronopoulos; Matthias Pfeifer; Vladimir Poroshin; Michaël Ughetto; Matthew J Martin; Hannah Thorpe; Aurelie Bornot; Paul D Smith; Ben Sidders; Jonathan R Dry; Miika Ahdesmäki; Ultan McDermott; Eliseo Papa; Krishna C Bulusu
Journal:  Nat Commun       Date:  2022-03-29       Impact factor: 14.919

Review 10.  Transcriptional Regulation of the Hippo Pathway: Current Understanding and Insights from Single-Cell Technologies.

Authors:  Sayantanee Paul; Shiqi Xie; Xiaosai Yao; Anwesha Dey
Journal:  Cells       Date:  2022-07-17       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.